Last reviewed · How we verify
Mirasol-treated Fresh Whole Blood — Competitive Intelligence Brief
phase 3
Pathogen reduction technology / Blood product
Hematology / Transfusion Medicine
Biologic
Live · refreshed every 30 min
Target snapshot
Mirasol-treated Fresh Whole Blood (Mirasol-treated Fresh Whole Blood) — Johns Hopkins University. Mirasol treatment uses riboflavin and ultraviolet light to inactivate pathogens and reduce white blood cells in fresh whole blood for transfusion.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mirasol-treated Fresh Whole Blood TARGET | Mirasol-treated Fresh Whole Blood | Johns Hopkins University | phase 3 | Pathogen reduction technology / Blood product | ||
| Riboflavin+UV RBC | Riboflavin+UV RBC | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | phase 3 | Pathogen reduction technology / Blood product treatment |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Pathogen reduction technology / Blood product class)
- Johns Hopkins University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mirasol-treated Fresh Whole Blood CI watch — RSS
- Mirasol-treated Fresh Whole Blood CI watch — Atom
- Mirasol-treated Fresh Whole Blood CI watch — JSON
- Mirasol-treated Fresh Whole Blood alone — RSS
- Whole Pathogen reduction technology / Blood product class — RSS
Cite this brief
Drug Landscape (2026). Mirasol-treated Fresh Whole Blood — Competitive Intelligence Brief. https://druglandscape.com/ci/mirasol-treated-fresh-whole-blood. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab